Neurosense Therapeutics Stock Analysis

Neurosense Stock Analysis Notes

About 35.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.65. Neurosense Therapeutics had not issued any dividends in recent years. NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. Neurosense Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people. To find out more about Neurosense Therapeutics contact Alon BenNoon at 972 9 799 6183 or learn more at https://www.neurosense-tx.com.

Neurosense Therapeutics Investment Alerts

Neurosense Therapeutics Upcoming and Recent Events

Neurosense Largest EPS Surprises

View All Earnings Estimates

Neurosense Stock Institutional Investors

Note, although Neurosense Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Neurosense Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.26 M.

Neurosense Profitablity

Management Efficiency

Neurosense Therapeutics has return on total asset (ROA) of (1.5079) % which means that it has lost $1.5079 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.9484) %, meaning that it created substantial loss on money invested by shareholders. Neurosense Therapeutics' management efficiency ratios could be used to measure how well Neurosense Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Neurosense Therapeutics' Return On Capital Employed is very stable compared to the past year. As of the 14th of December 2024, Return On Equity is likely to grow to 5.66, while Return On Tangible Assets are likely to drop (3.34). At this time, Neurosense Therapeutics' Total Assets are very stable compared to the past year. As of the 14th of December 2024, Net Tangible Assets is likely to grow to about 10.9 M, while Non Current Assets Total are likely to drop about 154 K.

Technical Drivers

As of the 14th of December 2024, Neurosense Therapeutics secures the Standard Deviation of 4.62, mean deviation of 3.31, and Risk Adjusted Performance of (0.04). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurosense Therapeutics, as well as the relationship between them.

Neurosense Therapeutics Price Movement Analysis

Neurosense Therapeutics Outstanding Bonds

Neurosense Therapeutics Predictive Daily Indicators

Neurosense Therapeutics Forecast Models

Neurosense Therapeutics' time-series forecasting models are one of many Neurosense Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Neurosense Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Neurosense Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Neurosense shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Neurosense Therapeutics. By using and applying Neurosense Stock analysis, traders can create a robust methodology for identifying Neurosense entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Neurosense analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Neurosense analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Neurosense Therapeutics stock analysis indicators help investors evaluate how Neurosense Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Neurosense Therapeutics shares will generate the highest return on investment. By understating and applying Neurosense Therapeutics stock analysis, traders can identify Neurosense Therapeutics position entry and exit signals to maximize returns.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.